Newsby HottubFor agents

Business and economy

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

3 outletsin 1 language and 3 countriesFirst reported , latest

Add to CRMJSONProspects as JSON

Every report 3 reports

  1. Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

    The Manila TimesPH

    Add to CRM
  2. Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

    Laotian TimesLA

    Add to CRM
  3. Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products – Thailand Business News

    Thailand Business NewsTH

    Add to CRM